Stoptions.aiStoptions.aiStoptions.aiStoptions.aiStoptions.ai
Powered by Amora Edge
How it worksResultsPricingMeet StoptieCompareBlog
Sign inStart free trial
Stoptions.ai
Powered by Amora Edge

Algorithmic scanning across the S&P 500 & Nasdaq 100. Stock & Options trade cards in your inbox by 9:35 AM ET every trading day.

Product
  • How it works
  • The Algorithm
  • Ticker Setups
  • Pricing
  • Morning Brief
  • Results
  • Compare tools
Account
  • Sign in
  • Start free trial
  • Give a gift
  • Dashboard
  • Settings
Company
  • About
  • Contact
  • Support
  • Blog
  • Sitemap
Legal
  • Terms of service
  • Privacy policy
  • Risk disclosure
  • Unsubscribe

© 2026 Stoptions.ai · All Rights Reserved

Not financial advice. Algo-generated setups are not personalised investment advice. Options trading involves significant risk of loss — past performance does not guarantee future results.

Chat with Stoptie
Stoptions.ai›Tickers›HAE
Last updated: Mon May 11, 2026 · 9:31 AM ET
↻ Next update: Thu May 14, 2026 · 9:31 AM ET

HAE Stock and Options Trade Setup — Haemonetics CorporationHAE logo

NYSE · Blood Management & Medical Devices · Low options liquidity · Mid cap · ~$3.8B

▲ Bullish setupPlasma DisposablesHospital SoftwareNiche Medical Device↑ Score +3 vs last update
65
Amora Edge Score
65
Top 40%
↑ +3 vs last update
Composite of EMA, RSI, RS vs SPY & volume · updated every 72h
62
HAE Win Rate
62%
6.2 of 10 HAE setups reached target
Tracks completed Stoptions setups on this ticker since Jan 2026
Why we cover HAE

Haemonetics is a medical device niche play with two high-return vectors. First, its plasma collection equipment serves commercial plasma fractionators — the raw material supply chain for immunoglobulin therapies — and plasma collection volumes are growing as the global immunotherapy market expands. Second, its hospital blood management software (BloodTrack, SafeTrace) is deeply embedded in hospital transfusion services with high switching costs and multi-year contracts. The recent NovaBay deal and Lexi-Comp divestitures signal management's focus on sharpening the portfolio. Gross margins in the plasma segment are exceptional (~55%+) because the disposables model creates recurring revenue with each collection. With new device approvals expanding the plasma yield per donation, the per-unit economics are improving for HAE's fractionator customers — a virtuous cycle for volume.

Score History & Signal Changelog

Preview data

This page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.

Score progression across 4 updates
Solid = composite · dashed = components
Signal changelog
DateUpdateScoreDeltaKey change
Apr 28#1 Created62—Page created. Plasma collection volumes recovering post-COVID lows.
May 1#2 Update63+1New NexSys PCS2 device driving yield improvements for fractionators.
May 7#3 Update64+1Q3 beat. Hospital segment margins improving post-divestiture cleanup.
May 11#4 Current65+1Portfolio now fully focused on blood management. Capital allocation improving.

Signal Breakdown

EMA Cross
Active
19/25
Price above 50-day EMA. Trend constructive after consolidation.
RSI Zone
Active
16/25
RSI 58. Constructive. Room for additional upside.
RS vs SPY
Active
16/25
HAE matching XLV healthcare sector performance.
Volume Surge
Holding
14/25
Moderate accumulation. Institutional ownership stable.

Today's Trade Card

Setup
HAE $65 CALL
Expires Jun 20, 2026
Premium
$2.00
Target
+70% premium
Stop loss
-50% premium
Breakeven
$67
Win prob.
38%
Sizing: Risk ≤ 0.75% of account
Greeks
Delta
0.38
Theta
-0.09
IVR
26%
IVR class
Low
Trade card available on Pro & Elite
Or start free trial →

Options Profile

Avg IV (30d)
28%
IVR range (52-wk)
18–48%
Put/call ratio
0.62
Avg daily vol.
1.0K contracts
Open interest
12K contracts
Next earnings
Aug 6, 2026 (est.)

Risks & Fundamentals

Every setup carries risk. Here's what could move HAE against you, plus the key stats that frame any position.

Beta
0.9
Market cap
~$3.8B
Risk level
Low-medium risk
Next earnings
Aug 6, 2026 (est.)
Key risks to monitor
  • 1.Plasma collection volume is sensitive to donor compensation rates and donor pool economics
  • 2.Hospital capital spending freezes can delay hardware placements
  • 3.Competition from Fresenius Kabi in plasma collection devices could pressure pricing
These are real risks to the long thesis, not a recommendation to short. Stoptions setups are short-dated and stop-protected; size accordingly.

HAE Options Setup — Frequently Asked Questions

Is HAE a good options trade today?+

Haemonetics Corporation (HAE) currently has an Amora Edge Score of 65/100, ranking it top 40%. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.

What is HAE's win rate on Stoptions.ai setups?+

HAE's historical win rate on closed Stoptions setups is 62%. Win rate is calculated as the percentage of past HAE trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.

What strike and expiry does Stoptions.ai suggest for HAE?+

The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.

How often is the HAE setup updated?+

Every 72 hours we refresh HAE's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If HAE drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.

What does the Amora Edge Score measure for HAE?+

The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to HAE: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is HAE outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. HAE currently scores 65.

How does HAE compare to other Blood Management & Medical Devices setups?+

HAE's sector rank and percentile against other Blood Management & Medical Devices tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Blood Management & Medical Devices Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.

Educational content only — not personalized investment advice. Options carry substantial risk.

The Weekly · Free

Get a Friday recap including setups like HAE.

Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.

No spam. One email Friday afternoon. Unsubscribe in one click.

More from Stoptions.ai
← All tickersHow the algorithm worksMorning BriefResultsPricing